INDV 6-K
Indivior Pharmaceuticals, Inc. (INDV)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of October 2024
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☒ Form 40-F ☐
EXHIBIT INDEX
| Exhibit No. | Description of Exhibit |
|---|---|
| 99.1 | Announcement sent<br>to the London Stock Exchange on October 01, 2024, titled<br>“Transaction in Own Shares”. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Indivior PLC | |
|---|---|
| Date: October 01, 2024 | /s/<br>Kathryn Hudson |
| Name:<br>Kathryn Hudson | |
| Title:<br>Company Secretary |
a3171g1
| Exhibit<br>99.1 |
|---|
INDIVIOR PLC
SHARE REPURCHASE PROGRAM
WEEKLY REPORT
October 1, 2024
INDIVIOR PLC ("Indivior") announces that it purchased for cancellation a total of 302,411 of its ordinary shares of $0.50 each through Morgan Stanley & Co. International Plc in the period from September 23, 2024, up to and including September 27, 2024, in connection with its $100m Share Repurchase Program. Aggregated information on the purchase of these shares can be found in the table below.
Following the purchase and cancellation of the above shares (including those purchased but not yet settled), Indivior has 129,614,897 ordinary shares of $0.50 each with voting rights in issue. There are no shares held in treasury.
The above figure (129,614,897) may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Indivior under the FCA's Disclosure Guidance and Transparency Rules.
All repurchases by Indivior are "On Exchange" transactions (as such term is defined in the rules of the London Stock Exchange) and "on market" for the purposes of the Companies Act 2006.
Aggregated information
| Trading<br>Date | Trading<br>Venue | Aggregated daily volume<br><br><br>(number of shares) | Daily weighted average<br><br><br>purchase price of the<br><br><br>shares (p) |
|---|---|---|---|
| 23/09/2024 | LSE | 30,649 | 698.59 |
| 23/09/2024 | BATE | 9,507 | 698.75 |
| 23/09/2024 | CHIX | 28,013 | 699.36 |
| 23/09/2024 | AQUIS | 5,904 | 695.15 |
| 24/09/2024 | LSE | 31,846 | 688.20 |
| 24/09/2024 | BATE | 13,212 | 688.46 |
| 24/09/2024 | CHIX | 26,373 | 687.71 |
| 24/09/2024 | AQUIS | 4,935 | 687.31 |
| 25/09/2024 | LSE | 27,123 | 688.19 |
| 25/09/2024 | BATE | 12,505 | 688.14 |
| 25/09/2024 | CHIX | 30,624 | 688.55 |
| 25/09/2024 | AQUIS | 5,114 | 688.89 |
| 26/09/2024 | LSE | 31,338 | 714.60 |
| 26/09/2024 | BATE | 8,311 | 715.14 |
| 26/09/2024 | CHIX | 29,953 | 715.94 |
| 26/09/2024 | AQUIS | 4,823 | 712.79 |
| 27/09/2024 | LSE | 1,285 | 728.63 |
| 27/09/2024 | CHIX | 896 | 729.60 |
Transaction details
In accordance with Article 5(1)(b) of the assimilated Market Abuse Regulation (EU) No 596/2014, as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018 and Commission Delegated Regulation (EU) 2016/1052, a full breakdown of the individual purchases of ordinary shares made by Morgan Stanley & Co. International Plc on behalf of Indivior during the above period as part of the Share Repurchase Program can be found at www.indivior.com/en/investors/shareholder-information/share-repurchase-program.
Indivior PLC's Legal Entity Identifier code is 213800V3NCQTY7IED471.
Contact:
Jason Thompson
Vice President, Investor Relations
1-804-402-7123